• Users Online: 35
  • Print this page
  • Email this page

 Table of Contents  
Year : 2020  |  Volume : 3  |  Issue : 3  |  Page : 1-2

Proactive Steps by the Ministry of AYUSH in mitigating COVID-19: An update on contribution of Siddha

Editor in Chief, Director General, Central Council for Research in Siddha (Ministry of AYUSH, Govt. of India), Arumbakkam, Chennai, Tamil Nadu, INDIA 600106, India

Date of Web Publication27-Sep-2021

Correspondence Address:
K Kanakavalli
Editor in Chief, Director General, Central Council for Research in Siddha (Ministry of AYUSH, Govt. of India), Arumbakkam, Chennai, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

How to cite this article:
Kanakavalli K. Proactive Steps by the Ministry of AYUSH in mitigating COVID-19: An update on contribution of Siddha. J Res Siddha Med 2020;3, Suppl S1:1-2

How to cite this URL:
Kanakavalli K. Proactive Steps by the Ministry of AYUSH in mitigating COVID-19: An update on contribution of Siddha. J Res Siddha Med [serial online] 2020 [cited 2022 May 23];3, Suppl S1:1-2. Available from: http://www.jrsm.com/text.asp?2020/3/3/1/326806

The current pandemic of COVID-19 is unprecedented. Coronaviruses chiefly cause respiratory tract infections and has high infectivity and mortality as well as heavy damage, such as severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS) on public health. Pneumonia associated with the 2019 novel coronavirus (2019- nCoV) emerged in Wuhan, China in December, 2019 and has spread rapidly with 68165877 confirmed COVID-19 cases, 1557385 confirmed deaths globally as of 10th December 2020[1]. This new type is said to be novel due to its complex envelop protein raised from multiple mutations. These mutations also alter the tissue tropism, eventually harbouring into varieties of hosts by damaging hosts immune response.

The symptomology of COVID-19 can be correlated to Kabha Suram including specific symptoms such as loss of taste mentioned in the Siddha classics. The Ministry of AYUSH has issued an advisory as early as 6th March 2020 prior to WHO declaring COVID-19 as pandemic. In this direction, the Government of Tamil Nadu also issued a G.O. (Ms). No. 201 dt. 23rd April 2020 Aarokyam special programme with AYUSH interventions for COVID-19 on 23rd April 2020. The proactive steps taken by the Ministry of AYUSH and collective team efforts put-forth by all stake holders enabled the Ministry of AYUSH to publish the Guidelines for Siddha practitioners for the management of COVID-19.

In this regard, the Interdisciplinary AYUSH Research and Development task force established by the Ministry of AYUSH has provided the framework and protocol to conduct three types of studies. Population health study - observation of people’s social behaviour patterns regarding the immune boosting measures of AYUSH/Siddha system of medicine through AYUSH Sanjivani[2]. Prophylactic intervention study on Health care workers, people at quarantine and isolation facilities and add-on therapy on COVID-19 patients[3].

Earlier, Siddha medicine was useful to mitigate the epidemic outbreaks of viral fevers like Chikungunya, Dengue and Bird flu, where the efficacy of the Siddha drugs was evaluated in research laboratories as well as the clinical centers and the findings led to administration of these Siddha drugs along with allopathy drugs in all the Government hospitals.

Siddhars have recommended certain basic lifestyle guidelines i.e., preventive measures that help to prevent diseases. Rejuvenating procedures known as Kaya Karpam act as immunomodulators. Siddha intervention activates physiological processes that influence metabolic and immunological status and offers palliative care even for patients with comorbidities. Therefore, Siddha medicine offers care, not only for chronic non communicable diseases, but also it is promising to combat the COVID-19 pandemic.

Prior to population based studies, in-silico studies and in-vitro studies of Kabha Sura Kudineer (KSK) exhibited high affinity for binding with SARS-COV2 protein spike and showed significant activity more or less to inhibit virus replication similar to standard drug Remdesivir[4]. Immuno-modulatory, thrombolytic and anti - viral activity of KSK has been established[5].

The interim results of prophylactic study entitled “a prospective Non-randomized Open label Controlled Interventional study on the effect of Siddha intervention – KSK as a Prophylactic measure among high risk population (Health Care Workers/Containment Zone population) exposed to COVID-19 (SIDDHALION)” as well as the preliminary results conducted at Govt. Stanley Medical College in study group (vitamin C with zinc and KSK) compared to control (vitamin C and zinc) are promising[6]. Few more clinical trials including double blind randomized controlled trials, the gold standard are in progress.

Effective functioning of Siddha Covid Care Centres (CCC) and its outcomes in successfully treating more than 28,000 patients has created an impact in the state of Tamil Nadu. The successful model developed in Chennai has been replicated in other parts of Tamil Nadu, and 33 exclusive Siddha CCC are providing holistic in-patient care free of cost to COVID-19 positive patients.

The hall mark of Siddha system of medicine is customized tailor-made medicine according to one’s constitution and presenting symptoms. Many modern private hospitals dispensed Siddha decoction/potion as part of hospital diet to willing patients. Such was the strength and impact of Siddha medicine which capitalized the current pandemic through comprehensive approaches mentioned in AYUSH systems.

Thus, Siddha system is gaining unabated popularity among the masses giving a major boost to Siddha system in mitigating this pandemic in an integrative manner.

  References Top

https://www.who.int/ Geneva. World Health Organization: c2020 [cited 2020 November 3]. Available from https://www.who.int/emergencies/diseases/novel-coronavirus-2019.  Back to cited text no. 1
AYUSH Sanjivani android application. Available from https://play.google.com/store/apps/details?id=com. negd.ayushfeedback.  Back to cited text no. 2
Interdisciplinary AYUSH Research and Development Task Force. Ministry of AYUSH, Govt. of India. Clinical Trials on AYUSH Interventions for COVID-19: Methodology and Protocol Development. April 2020;1-75.  Back to cited text no. 3
Kiran G, Karthik L, Shree Devi MS, Sathiyarajeswaran, P, Kanakavalli K, Kumar KM, Ramesh Kumar D. In Silico computational screening of Kabasura Kudineer - Official SiddhaFormulation and JACOM against SARS-CoV-2 spike protein. Journal of Ayurveda and Integrative Medicine 2020.  Back to cited text no. 4
Sathiyarajeswaran P, Arivarasan, Vishnu Kirthi, Shree Devi MS, Kanakavalli, Ramesh Kumar D, Karthik L. In-Vitro Immunomodulatory Activity and Thrombolytic Potential of Kabasura Kudineer (KSK), an Official Siddha Polyherbal Formulation 2020. Available at SSRN: https://ssrn.com/abstract=3670659 or http://dx.doi.org/10.2139/ssrn.3670659.  Back to cited text no. 5
Natarajan S, Anbarasi C, Sathiyarajeswaran P, Manickam P, Geetha S, Kathiravan R, Prathiba P, Pitchiahkumar M, Parthiban P, Kanakavalli K, Balaji P. The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary ofa study protocol for a randomised controlled trial 2020;21(1):892.  Back to cited text no. 6


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded39    
    Comments [Add]    

Recommend this journal